Actively Recruiting

Phase 2
Age: 0 - 31Years
All Genders
NCT04301843

Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma

Led by Giselle Sholler · Updated on 2026-02-03

131

Participants Needed

31

Research Sites

679 weeks

Total Duration

On this page

Sponsors

G

Giselle Sholler

Lead Sponsor

K

K C Pharmaceuticals Inc.

Collaborating Sponsor

AI-Summary

What this Trial Is About

Difluoromethylornithine (DFMO) will be used in an open label, multicenter, study in combination with etoposide for subjects with relapsed/refractory neuroblastoma.

CONDITIONS

Official Title

Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma

Who Can Participate

Age: 0 - 31Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients must have a confirmed diagnosis of neuroblastoma and be 30.99 years old or younger with relapsed or refractory disease.
  • Patients must have completed at least 4 cycles of aggressive multi-drug chemotherapy.
  • For Arms 1 and 2: No active disease shown by CT/MRI and MIBG or PET scans, and no evidence of bone marrow metastasis.
  • Enrollment must occur within 60 days of last therapy dose.
  • Patients must have recovered from prior treatments according to specified timelines for chemotherapy, growth factors, biologic agents, immunotherapy, monoclonal antibodies, radiation, stem cell transplant, and MIBG therapy.
  • Lansky or Karnofsky Performance Scale score of 60% or higher.
  • Life expectancy greater than 2 months.
  • Adequate organ function confirmed within 7 days before first dose.
  • Negative pregnancy test and agreement to use birth control if of childbearing potential; breastfeeding must stop.
  • Written informed consent must be obtained.
Not Eligible

You will not qualify if you...

  • Body surface area less than 0.25 m2.
  • Prior use of DFMO at doses higher than 1000 mg/m2 twice daily.
  • Prior treatment with DFMO combined with etoposide.
  • Currently receiving another investigational drug.
  • Currently receiving other anticancer agents or not fully recovered from prior chemotherapy effects.
  • Uncontrolled infections.
  • Inability or unlikely compliance with safety monitoring requirements as judged by the investigator.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 31 locations

1

University of Alabama/Children's of Alabama

Birmingham, Alabama, United States, 35201

Actively Recruiting

2

Arkansas Children's Hospital

Little Rock, Arkansas, United States, 72202

Actively Recruiting

3

UCSF Benioff Children's Hospital Oakland

Oakland, California, United States, 94609

Actively Recruiting

4

Rady Children's Hospital

San Diego, California, United States, 92123

Actively Recruiting

5

Connecticut Children's Hospital

Hartford, Connecticut, United States, 06106

Actively Recruiting

6

Arnold Palmer Hospital for Children

Orlando, Florida, United States, 32806

Actively Recruiting

7

St. Joseph's Children's Hospital

Tampa, Florida, United States, 33614

Actively Recruiting

8

Augusta University Health

Augusta, Georgia, United States, 30912

Actively Recruiting

9

University of Iowa

Iowa City, Iowa, United States, 52242

Actively Recruiting

10

Norton Children's Research Institute/Affiliated with University of Louisville School of Medicine

Louisville, Kentucky, United States, 40201

Actively Recruiting

11

Helen DeVos Children's Hospital

Grand Rapids, Michigan, United States, 49503

Actively Recruiting

12

Children's Hospital and Clinics of Minnesota

Minneapolis, Minnesota, United States, 55404

Actively Recruiting

13

Children's Mercy Hospitals and Clinics

Kansas City, Missouri, United States, 64108

Actively Recruiting

14

Cardinal Glennon Children's Hospital

St Louis, Missouri, United States, 63104

Actively Recruiting

15

Hackensack University Medical Center

Hackensack, New Jersey, United States, 07601

Actively Recruiting

16

Levine Children's Hospital

Charlotte, North Carolina, United States, 28204

Actively Recruiting

17

Cleveland Clinic Children's

Cleveland, Ohio, United States, 44195

Actively Recruiting

18

Randall Children's Hospital

Portland, Oregon, United States, 97227

Actively Recruiting

19

Penn State Milton S. Hershey Medical Center and Children's Hospital

Hershey, Pennsylvania, United States, 17033

Actively Recruiting

20

Hasbro Children's Hospital

Providence, Rhode Island, United States, 02901

Actively Recruiting

21

Medical University of South Carolina

Charleston, South Carolina, United States, 29425

Actively Recruiting

22

Dell Children's Blood and Cancer Center

Austin, Texas, United States, 78723

Actively Recruiting

23

Children's Medical Center Dallas

Dallas, Texas, United States, 75235

Actively Recruiting

24

Children's Hospital of The King's Daughters

Norfolk, Virginia, United States, 23507

Actively Recruiting

25

Medical College of Wisconsin

Milwaukee, Wisconsin, United States, 53226

Actively Recruiting

26

Alberta Children's Hospital

Calgary, Alberta, Canada, AB T3B 6A8

Actively Recruiting

27

CancerCare Manitoba

Winnipeg, Manitoba, Canada, MB R3E 0V9

Actively Recruiting

28

UHC Sainte-Justine

Montreal, Quebec, Canada, QC H3S 2G4

Actively Recruiting

29

Montreal Children's Hospital

Montreal, Quebec, Canada, QC H4A 3H9

Actively Recruiting

30

CHUQ

Québec, Quebec, Canada, QC G1V 4W6

Actively Recruiting

31

CIUSSS de l'Estrie-CHUS

Sherbrooke, Quebec, Canada, QC J1H 5H3

Actively Recruiting

Loading map...

Research Team

B

BCC Enroll

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma | DecenTrialz